Enanta Q3 net loss $18.3M ($0.85/sh); RSV topline data due Sept

ENANTA PHARMACEUTICALS INC

2025-Q3 EPS reported -$2.96 vs consensus -$1.04 ▼ miss (-184.2%)

Revenue of $18.3M from AbbVie royalties; net loss narrowed vs $22.7M Q3 2024.
Cash & securities $204.1M; cash runway into fiscal 2028.
RSVHR Phase 2b fully enrolled (186 patients); topline data expected September.
IND-enabling studies ongoing for oral KIT inhibitor EPS-1421; STAT6 candidate selection in 2H 2025.
AbbVie received FDA approval for expanded MAVYRET indication in acute HCV.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.